Site navigation

Navigation

Diabetes (type 1 and 2) - inhaled insulin

Inhaled insulin for the treatment of types 1 and 2 diabetes

Status: History
Expected date of issue: December 2006
Referral date: January 2100
Wave: 10
Process: MTA
Topic area:
  • Endocrine, nutritional and metabolic
 

NICE project team

Executive Lead: Andrea Sutcliffe
Technical Lead: Elisabeth George
Communications manager: Sarita Tamber
Project manager: Alana Miller
Assessment group: Aberdeen HTA Group
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: April 2005
Information meeting with consultees: 29 July 2005
Closing date for invited submissions / evidence submission: 21 September 2005
Final scope published: June 2005
1st appraisal committee meeting: 21 March 2006
2nd appraisal committee meeting 26 May 2006
3rd appraisal committee meeting: 23 August 2006
Top


 

Consultees and Commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Pfizer Ltd (exubera)

Patient / Carer Groups

  • Diabetes UK
  • Insulin Dependent Diabetes Trust

Professional Groups

  • Association of British Clinical Diabetologists
  • Association of Diabetes Specialist Nurses
  • British Dietetic Association
  • Royal College of Nursing
  • RoyalCollegeof Physicians

Others

  • Department of Health
  • South Warwickshire PCT

General

  • NHS Quality Improvement Scotland
  • EUCOMED

Comparator Manufacturers

  • Novo Nordisk Ltd
  • Eli Lilly & Co Ltd

Assessment Team

  • Aberdeen HTA Group
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • Type 2 Diabetes Guideline Development Group

Associated Public Health Groups

  • None

Research Groups

  • None

Top


 

Project history

Date Update
16 August 2004 Initial schedule provided
24 August 2004 Title changed and Communications Manager named
14 January 2005 Technology Appraisal Project Manager changed
16 March 2005 Information meeting for consultees confirmed as 29 July 2005
6 April 2005 Technical lead appointed.
12 May 2005 Draft scope and provisional matrix of consultees and commentators added.
23 May 2005 Dates of appraisal committeee meetings and expected publication date amended.
9 June 2005 Change to date of draft scope for consultation and project manager.
Date Update
20 June 2005 Final scope and final matirx of commentators and consultees published together with comments on draft scope and matrix.
1 September 2005 Final protocol published.
30 January 2006 Certain stakeholders removed from lists.
1 February 2006 Stakeholder list amended.
7 February 2006 Stakeholder list amended.
21 June 2006 ACD and consultee comments published
27 July 2006 Expected date of issue changeed to November 2006 and third appraisal committee meeting added.
25 October 2006

FAD issued on 12 October 2006:-

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on ' Diabetes (type 1 and 2) - inhaled insulin ' and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5:00pm on 27th October 2006.
Top


 

Key documents

This page was last updated:   25 October 2006